Indian pharma exports to grow by 20% to over $11 billion this year

22 February 2011

As a result of an increasing number of drugs turning off-patent and greater acceptance of generic drugs in regulated markets, pharmaceutical exports from India will reach 500 billion rupees ($11.06 billion) in the current fiscal, according to the Pharmaceutical Exports Promotion Council’s (Pharmexcil) executive director, PV Appaji.

He said that that Indian pharmaceutical exports in the last fiscal year amounted to 420 billion rupees, and he expect this to grow by 20% this year, as the sector is coming of the recession effect, reports the local newspaper the Financial Chronicle.

During 2009-10, pharmaceutical exports saw only 4.13% growth over the previous year. While the effect of slowdown on the other sectors was visible during 2008-09, pharmaceuticals witnessed it only during 2009-10. “The inventories of drugs lasted for the 2009-10 period when the slowdown was at its peak,” Mr Appaji said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Generics